Earl Martin Douglas
SVP, General Counsel · 2 filings · Latest: Aug 21, 2026
Allogene Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ALLO | Earl Martin Douglas | SVP, General Counsel | Aug 21, 2026 | Sale | $2.12 | 29,697 | $63.0K | 488,267 | |
ALLO | Douglas Earl Martin | — | Aug 21, 2026 | Proposed Sale | $2.12 | 29,697 | $63.0K | — | |
ALLO | Earl Martin Douglas | SVP, General Counsel | Feb 2, 2026 | Sale | $1.76 | 22,900 | $40.3K | 564,948 | |
ALLO | EARL DOUGLAS | — | Feb 2, 2026 | Proposed Sale | $1.76 | 22,900 | $40.2K | — | |
ALLO | Douglas Earl Martin | — | Feb 3, 2025 | Proposed Sale | $1.71 | 6,404 | $11.0K | — | |
ALLO | Douglas Earl Martin | — | Aug 21, 2024 | Proposed Sale | $2.79 | 28,310 | $78.8K | — |